{"nctId":"NCT00598806","briefTitle":"Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)","startDateStruct":{"date":"2007-08","type":"ACTUAL"},"conditions":["Bladder Cancer"],"count":812,"armGroups":[{"label":"Apaziquone","type":"EXPERIMENTAL","interventionNames":["Drug: Apaziquone","Procedure: TURBT"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Procedure: TURBT"]}],"interventions":[{"name":"Apaziquone","otherNames":["EOquinÂ®, Qapzola"]},{"name":"Placebo","otherNames":[]},{"name":"TURBT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAll of the following questions must be answered \"Yes\" in order for the patient to participate in the study.\n\n1. Has the patient given written informed consent?\n2. Is the patient at least 18 years old?\n3. Does the patient have transitional cell carcinoma of the bladder with clinically apparent tumor Ta, grade G1-G2?\n4. If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception?\n5. If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 14 days?\n6. Is the patient willing and able to abide by the protocol?\n\nExclusion Criteria:\n\nAll of the following questions must be answered \"No\" in order for the patient to participate in the study.\n\n1. Does the patient have more than 5 bladder tumors?\n2. Does any single bladder tumor exceed 3.5 cm in diameter?\n3. Does the patient have a single, primary bladder tumor \\<0.5 cm and has no previous diagnosis of bladder cancer?\n4. Has the patient ever received EOquin(r)?\n5. Does the patient have, or has the patient ever had, any bladder tumor known to be other than tumor Ta or grade G1 or G2 (low grade \\[WHO/ISUP classification\\])?\n6. Does the patient have, or has the patient ever had any bladder tumor with histology other than transitional cell carcinoma?\n7. Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?\n8. Does the patient have an active urinary tract infection?\n9. Does the patient have a bleeding disorder or a screening platelet count \\< 100 x 109/L?\n10. Does the patient have any unstable medical condition that would make it unsafe for him/her to undergo TURBT under general or spinal anesthesia?\n11. Does the patient have screening hemoglobin \\< 10 mg/dL, a screening absolute neutrophil count \\< 1.5 x 109/L?\n12. Does the patient have a known immunodeficiency disorder?\n13. Has the patient received any investigational treatment within the past 30 days?\n14. Is the patient breast feeding?\n15. Does the patient have a history of interstitial cystitis?\n16. Does the patient have a history of allergy to red color food dye?\n17. Has the patient had transitional cell carcinoma of the bladder within the past 4 months?","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence Rate at 2 Years","description":"The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"138","spread":null}]},{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence","description":"The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"0.5"},{"groupId":"OG001","value":"16.7","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Progression Rate at 2 Years","description":"The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"261","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression","description":"The number of months from randomization to progression to either a higher stage or grade of the patient's bladder tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"0.3"},{"groupId":"OG001","value":"21.9","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Number of Recurrences Per Patient","description":"The number of histologically confirmed recurrences during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.98"},{"groupId":"OG001","value":"0.9","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Disease-Free Interval","description":"The number of months from randomization to histologically confirmed progression of the patient's bladder tumor or death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"0.3"},{"groupId":"OG001","value":"21.9","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival","description":"The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor or death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"0.5"},{"groupId":"OG001","value":"16.4","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The number of months from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"0.14"},{"groupId":"OG001","value":"20.2","spread":"0.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":96,"n":402},"commonTop":["Urinary tract infection","Dysuria","Haematuria","Pollakiuria","Micturition urgency"]}}}